Serina Therapeutics SER Insider Ownership

NYSE SER

$1.77 +0.00 (+0.04%)

As of: Oct 22, 2026 · 11:07 AM EDT

Insider Holdings by Owner

8.86Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

34.84%

▼-0.147% pp QoQ

Shares Held by Insiders

8.85Mn

filed for Sep 2026

▼-0.42% QoQ

Shares Outstanding

25.40Mn

25,400,000 shares

Direct Holdings

8.62Mn

Indirect: 231.71K

Net Shares Traded (QoQ)

-37.23K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 16, 2026

In the last 12 months, insiders at Serina Therapeutics made open-market purchases of $77,930 (43.87K shares) and open-market sales of $478,947 (149.5K shares).

Counted by insider, open-market buying of SER stock in the past 12 months came from 4 insiders and selling from one insider.
Among Serina Therapeutics' insiders, the largest open-market purchases in the past 12 months were by Karen J. Wilson (Director), totaling $54,750 (30.1K shares), most recently on June 12, 2026.
On the sell side, Randall Moreadith (Chief Scientific Officer) led open-market sales of Serina Therapeutics stock over the past 12 months with $478,947 (149.5K shares), most recently on March 23, 2026.
The latest open-market trade in SER stock by an insider was a purchase of 1K shares for $2,030 by Stephen K. Brannan (Director) on July 7, 2026.
Away from the open market, SER insiders received 77.97K shares in stock awards and acquired 8.81Mn shares through option exercises and conversions over the last 12 months.
Business Quant data shows Serina Therapeutics insiders holding 8.85Mn shares in total in their latest Form 4 filings, down 0.42% from 8.89Mn shares at the end of Q2 2026.
Of the 8.85Mn shares held by Serina Therapeutics insiders, 8.62Mn shares (97.38%) are held directly and 231.71K shares (2.62%) indirectly, through trusts, partnerships, family members and other entities.
Per Business Quant, 6 insiders of SER hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
SER's three largest insider shareholders, per their latest Form 4 filings, are Gregory Bailey (Director, 8.56Mn shares), Jay Venkatesan (Director, 232.29K shares) and Karen J. Wilson (Director, 30.1K shares).
Gregory Bailey holds 96.77% of the combined insider position in Serina Therapeutics.
Institutions owned 5.54% of SER shares as of Q2 2026; insiders' latest Form 4 filings account for about 34.84%, leaving roughly 59.62% with other investors, including the public.
Over the past 12 months, 11 insiders reported transactions in Serina Therapeutics stock in 50 Form 4 filings.
The insider holdings and trades above for Serina Therapeutics reflect Form 4 filings through July 23, 2026.

Form 4 Holdings

Insiders Holding SER

Insiders 8

Shares held 8.86Mn

Of outstanding 34.87%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Gregory Bailey	Director	8,564,382	0	8,564,382	96.7%	22 Jun, 2026
2	Jay Venkatesan	Director	589	231,705	232,294	2.6%	22 Jun, 2026
3	Steven Mintz	Director	0	25,973	25,973	0.3%	16 Sep, 2024
4	Richard Peter Marshall	Director	12,183	0	12,183	0.1%	22 May, 2026
5	Karen J Wilson	Director	10,100	0	10,100	0.1%	15 Jun, 2026
6	Steven A Ledger	Chief Executive Officer	10,100	0	10,100	0.1%	27 May, 2026
7	Michael D West	Chief Executive Officer	1,194	0	1,194	0.0%	14 Mar, 2023
8	Stephen K. Brannan	Director	1,000	0	1,000	0.0%	09 Jul, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

285 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
22 Jul, 2026	Farrell Simon	Director	Acquired A	30,500	$0.00	$0	30,500	Direct
07 Jul, 2026	Stephen K. Brannan	Director	Acquired P	1,000	$2.03	$2.03K	1,000	Direct
17 Jun, 2026	Stephen K. Brannan	Director	Acquired A	15,250	$0.00	$0	15,250	Direct
22 May, 2026	Jay Venkatesan	Director	Acquired P	589	$1.78	$1.05K	589	Direct
17 Jun, 2026	Gregory Bailey	Director	Acquired C	1,770,805	$2.25	$3.98Mn	1,897,445	Direct
17 Jun, 2026	Richard Peter Marshall	Director	Acquired A	15,250	$0.00	$0	15,250	Direct
17 Jun, 2026	Jay Venkatesan	Director	Acquired C	224,152	$2.25	$504.34K	231,705	Indirect
17 Jun, 2026	Karen J Wilson	Director	Acquired A	15,250	$0.00	$0	15,250	Direct
17 Jun, 2026	Gregory Bailey	Director	Acquired C	6,666,667	$2.25	$15.00Mn	8,564,382	Direct
17 Jun, 2026	Jay Venkatesan	Director	Acquired A	15,250	$0.00	$0	15,250	Direct
17 Jun, 2026	Gregory Bailey	Director	Acquired A	15,250	$0.00	$0	15,250	Direct
17 Jun, 2026	Jay Venkatesan	Director	Disposed C	96,525	$2.25	$217.18K	0	Indirect
17 Jun, 2026	Gregory Bailey	Director	Acquired A	3,333,333	$0.00	$0	3,333,333	Direct
17 Jun, 2026	Gregory Bailey	Director	Disposed C	762,548	$2.25	$1.72Mn	0	Direct
11 Jun, 2026	Karen J Wilson	Director	Acquired P	5,100	$1.75	$8.90K	5,100	Direct
12 Jun, 2026	Karen J Wilson	Director	Acquired P	5,000	$1.77	$8.85K	10,100	Direct
26 May, 2026	Steven A Ledger	Chief Executive Officer	Acquired A	10,100	$1.93	$19.49K	10,100	Direct
21 May, 2026	Randall Moreadith	Chief Scientific Officer	Acquired A	85,558	$0.00	$0	85,558	Direct
21 May, 2026	Srini Tenjarla	Svp, Cmc Formulation	Acquired A	85,558	$0.00	$0	85,558	Direct
21 May, 2026	Karen J Wilson	Director	Acquired P	10,000	$1.77	$17.70K	10,000	Direct

Showing 1 to 20 of 285 transactions